Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Bullboard Posts
Comment by skyplton Aug 01, 2019 4:25pm
98 Views
Post# 29986012

RE:Is $120-$130 Million Possible?

RE:Is $120-$130 Million Possible?Well gottahunch...apparently you were not missing anything.

Sky

gottahunch wrote:

Let's review CC Pharma and Aphria Revenue.


From the NR below:

During 2018, CC Pharma generated revenue of approximately €262 million, with EBITDA of approximately €10.5 million.


https://www.prnewswire.com/news-releases/aphria-completes-acquisition-of-cc-pharma-leading-german-pharmaceutical-and-medical-cannabis-distributor-300775086.html


As per Google currency conversion today:

262,000,000 Euro equals $382,547,510.00 Canadian Dollars. Seems like the last time I had checked it was closer to 400 million CAD for the year but perhaps there has been currency fluctuation since then. Anyway, divide this by 4 quarters and you get $95,636,877 a quarter. This should be the rough revenue for CC Pharma this quarter. Add to this what you think Aphria will do.


Revenue from Cannabis produced ending Feb 28th quarter was $17,862,000. Revenue from quarter before that ending November $24,524,000.  We know that sales have been increasing each month since legalization and in April physical stores opened in Ontario. Aphria has been working on their packaging issues and pushing out inventory.  Would it not be conservative to assume at a minimum that Aphria sold at least the same as what they sold for the q ending November? 95,636,877 + 24,524,000 = $120,160,877. Now that is just based on possible previous q numbers but could it not even be higher? Is 120-130 million possible?


I am also wondering about their inventory numbers and how cloning plants for expansion may affect what they actually harvested. But to me the estimates of 75 million US = $99 Million CAD seem low and I'm scratching my head about this estimate, as it seems like CC Pharma alone could be 95 million. So I am wondering WTF I am missing here?

Thoughts?
GLTA

 


Bullboard Posts